Combination of aurora kinase inhibitors and anti-cd20 antibodies

Abstract

The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.

1 . A method of treating a patient suffering from a hematological malignancy, comprising administering to the subject a therapeutically effective amount of an Aurora kinase inhibitor simultaneously with or consecutively with an anti-CD20 antibody, wherein the hematological malignancy is Diffuse Large B-cell lymphoma, the anti-CD20 antibody is rituximab, and the Aurora kinase inhibitor is 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid, or a pharmaceutically acceptable salt thereof. 
     
     
         2 - 4 . (canceled) 
     
     
         5 . The method of  claim 1 , wherein the patient was treated previously with an anti-CD20 antibody. 
     
     
         6 .- 9 . (canceled) 
     
     
         10 . The method of  claim 1 , wherein the Aurora kinase inhibitor is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate.